CCR6 and neoplasm: The HER2-CXCR5-CCR6-CAR T group demonstrated the most effective control over orthotopic HCC827-Luciferase tumors, with a final tumor bioluminescence photon flux of 14,600 ± 5,313.67 p/s, highlighting the synergistic benefits of CXCR5 and CCR6 co-expression (Fig. 4B, C).